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Abstract: 18 
Members of the epidermal growth factor receptor family (ErbB family) possess a wide 19 
distribution and diverse functions ranging from cellular growth to migration and apoptosis. 20 
Though highly implicated in a variety of cancers, their involvement in infectious disease is 21 
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less recognised. A growing body of evidence now highlights the importance of the ErbB 22 
family in a variety of infections. Their role as growth factor receptors, along with other 23 
characteristics, such as surface expression and continuous intracellular trafficking, make this 24 
receptor family ideally placed for exploitation by pathogens. Herein, we review our current 25 
understanding of the role of the ErbB family in the context of infectious disease, exploring 26 
the mechanisms that govern pathogen exploitation of this system. 27 
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ErbB receptors, a gatekeeper of infectious disease 28 
The co-evolution of host and pathogen has ensured that while the host attempts to 29 
maintain immunological homeostasis, invading organisms look to manipulate host biology 30 
for their own benefit. A central role in this co-evolution is played by host cell receptors 31 
which can both recognise microbes and manipulate cellular responses to them. As such, 32 
pathogens have developed mechanisms to subvert host cell receptors for their own needs; 33 
the ErbB family is one group of host receptors involved in such a relationship.  34 
 35 
The ErbB receptor tyrosine kinase family consists of four members, ErbB1 (epidermal 36 
growth factor receptor, EGFR), ErbB2, ErbB3 and ErbB4, which are expressed on a plethora 37 
of cell types, including epithelial [1], endothelial [2] , neuronal and glial [3], bone [4], 38 
adipose [5], liver [6] and cardiovascular cells [7]. Following ligand binding and activation, 39 
oligomerisation of ErbB family members occurs [8]. ErbB signalling is then induced through 40 
phosphorylation of intracellular domains, resulting in the activation of several major 41 
intracellular signalling pathways, including mitogen activated protein (MAP) kinase, nuclear 42 
factor kappa B (NF-ĸB), phosphoinositide 3 (Pi3) kinase and janus kinase/signal transducer 43 
and activator of transcription (JAK/STAT) pathways. ErbB associated signalling pathways 44 
govern a wide variety of outcomes including cell survival, proliferation, cell death/apoptosis, 45 
angiogenesis, adhesion, differentiation and migration/invasion. 46 
 47 
The majority of studies investigating the role of ErbB receptors in infectious disease focus on 48 
pathogens that primarily infect mucosal surfaces. In this context, ErbB expression on 49 
epithelial cells, the primary point of pathogen contact, plays a crucial role. As membrane 50 
receptors, ErbB functionality and localisation make them well positioned to provide a direct 51 
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point of contact and entry into host cells. Not only are ErbB family members regularly 52 
endocytosed during their normal life cycle, but pathogen-ErbB ligation [9,10] and ErbB 53 
receptor signalling cascades [11–14] can contribute to cellular entry of a diverse range of 54 
microbes. Pathogen-mediated hijacking of ErbB signalling pathways also results in prolonged 55 
host cell survival [11,12,15–17] as well as altered immune responses [18–26], which may, in 56 
turn, enhance pathogen persistence. Crucially, however, their role as growth factor 57 
receptors may be required by intracellular organisms, dependent on host cell machinery for 58 
self-propagation, such as Hepatitis C virus (HCV) [15,27–29], Epstein Barr virus (EBV) [30] 59 
and Human papilloma viruses (HPV) [31]. These pathogens are able to regulate transition 60 
through host cell cycle checkpoints and indeed their association with ErbB receptors is 61 
linked to cellular transformation and oncogenesis. A direct correlation, however, between 62 
regulation of the cell cycle and oncogenesis, has not been shown. 63 
 64 
ErbB receptors clearly exhibit a diverse and important range of functions. This review 65 
attempts to detail our current understanding of their role of during infection (summarised in 66 
Table 1) and contribution towards disease.  67 
 68 
ErbB-dependent pathogen entry and invasion: 69 
Influenza A virus (IAV), respiratory syncytial virus (RSV) and coronaviruses are respiratory 70 
pathogens that have been extensively studied in airway epithelial cells with regard to their 71 
replication cycle and the host response they elicit. More recently, it has been shown that all 72 
three viruses are able to utilise EGFR (ErbB1) for host cell entry. While RSV [32,33] and 73 
coronaviruses [34] induce EGFR-dependent macropinocytosis, a non-selective mechanism of 74 
internalising large bodies of extracellular material, IAV induces lipid-raft clustering on 75 
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surface membranes, resulting in EGFR activation and internalisation of both virus and EGFR 76 
[35]. Interestingly, lipid rafts are also important for IAV viral budding and exit from host cells 77 
[36–39]. Newly synthesised structural IAV proteins, hemagglutinin (HA) and neuraminidase 78 
(NA), can assemble at the cytoplasmic leaflet of lipid rafts [40,41], providing a platform for 79 
nascent viral proteins to cluster at, form progeny virus and from which to bud [42]. Given 80 
that EGFR localises at lipid rafts [43], a potential role for EGFR during viral exit may also exist 81 
(see Outstanding Questions Box). Additionally, the intestinal bacterial pathogen 82 
Campylobacter jejuni [44] also requires lipid-raft clustering and activation of raft-associated 83 
proteins, integrin-β1, EGFR and platelet derived growth factor receptor (PDGFR) for 84 
induction of filopodia formation and bacterial invasion. 85 
 86 
While such pathogens exploit host internalisation mechanisms, some large microbes appear 87 
to have adopted a different mechanism of EGFR-mediated host cell entry, involving 88 
manipulation of epithelial junction proteins. The integrity of the epithelium is critical for 89 
host defence and is maintained by a variety of proteins located at the interface of adjacent 90 
epithelial cells, which include tight junctions, adherens, desmosomes and gap junctions. 91 
Such proteins help to maintain intimate contact between neighbouring cells, cellular 92 
anchorage and polarity, as well as the paracellular flux of solutes [45–48].  93 
 94 
With this in mind, it becomes apparent that targeting such proteins may provide a means of 95 
breaching this primary defence barrier, and indeed EGFR has been implicated in modulation 96 
of such junction proteins. The bacterial species Salmonella enterica serovar Typhimurium is 97 
able to activate EGFR and induce expression of Claudin-2, a channel forming tight-junction 98 
protein [49] which results in gut epithelium invasion [50]. Claudin-2 activation during 99 
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infection is dependent on EGFR phosphorylation, as evidenced by a reduction in bacterial 100 
load following siRNA-mediated EGFR downregulation [50]. An alternative mechanism 101 
targeting junction proteins for cell entry is utilised by Staphylococcus aureus. Cleavage of 102 
occludin and E-cadherin, following EGFR activation, facilitates transmigration of S. aureus 103 
through cell-cell junctions, and inhibition of EGFR activity prevents S. aureus migration 104 
through an epithelial monolayer [13]. Additionally, Neisseria gonorrhoeae induces an EGFR-105 
dependent mechanism of β-catenin redistribution from apical junctions to the cytoplasm, 106 
resulting in weakened apical junctions and gonococcal transmigration across the epithelium 107 
[51].  108 
Unsurprisingly, enhanced epithelial cell proliferation and improved barrier integrity can 109 
provide protective functions against pathogen invasion [52–54], and interestingly both 110 
factors can be regulated by ErbB receptors. A protective role of ErbB receptors against 111 
infection would be interesting to explore in this context (see Outstanding Questions). 112 
 113 
The second ErbB family member, ErbB2, is also targeted by pathogens for cellular entry. 114 
Mycobacterium leprae directly binds and activates ErbB2 to induce downstream Erk1/Erk2 115 
signalling and bacterial invasion of Schwann cells. Trastuzumab, a potent ErbB2-targeted 116 
monoclonal antibody, abrogated both in vitro and in vivo M. leprae-induced myelin damage, 117 
highlighting ErbB2 as a crucial factor for leprosy disease [14]. The bacterium Neisseria 118 
meningitidis also induces recruitment and aggregation of ErbB2, but not other ErbB family 119 
members, on endothelial cell membranes, directly beneath sites of bacterial colony 120 
formation. Subsequent activation of ErbB2 and downstream Src-dependent signalling led to 121 
internalisation of N. meningitides and invasion of target cells [2]. Additionally, the fungus 122 
Candida albicans utilises both EGFR and ErbB2 to induce endocytosis and invasion into 123 
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epithelial cells [55,56]. Reduced severity of oropharangeal candidiasis is observed in mice 124 
following treatment with a dual EGFR/ErbB2 kinase inhibitor [55]. Liu et al. also document 125 
ErbB2 activation during vulvovaginal candidiasis in humans [57]. 126 
 127 
Another pathogen-mediated mechanism that promotes host cell entry may involve 128 
increased numbers of ErbB receptors at the cell surface. ErbB receptors spend the majority 129 
of their life span at the surface of cell membranes but continually undergo internalisation as 130 
part of normal processing. The fate of internalised receptors has important consequences 131 
for the cell. Potential receptor outcomes following endocytosis, include, recycling back to 132 
the surface (associated with proliferation), transport to other cellular compartments such as 133 
multivesicular bodies, the nucleus or mitochondria (related to homeostasis), or being 134 
targeted for degradation (thought to promote cell death) [58–60]. Pathogens appear to 135 
target these trafficking pathways for their own benefit. For example, Hepatitis C virus (HCV) 136 
induces the upregulation of host derived Netrin-1, which suppresses EGFR recycling, 137 
resulting in enhanced levels of surface EGFR, EGFR activation and subsequent viral 138 
endocytosis [27], which occurs via virus-induced EGFR and host-derived CD81 protein 139 
binding [28]. Additionally, the ErbB ligand neuregulin-1 has been implicated in enhancing 140 
EGFR and ErbB2 surface expression during HCV infection [29].  N. gonorrhoeae-induced 141 
upregulation of several ErbB ligands was also found to coincide with translocation of both 142 
EGFR and ErbB2 receptors to apical surfaces, following infection. This disruption of normal 143 
receptor distribution within polarised epithelial cells led to enhanced bacterial invasion and 144 
upregulation of EGFR-ligand mRNA was also observed [61]. Conversely, however, 145 
Escherichia coli-mediated disruption of endosome recycling leads to reduced surface EGFR, 146 
transferrin and β1-integrin expression [62]. Additional examples of EGFR-dependent 147 
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mechanisms of host cell entry include Chlamydia pneumoniae Pmp21-mediated recruitment 148 
of EGFR [10], and EGFR-dependent formation of HPV type 16 (HPV16), Annexin A2 and 149 
S100A10 heterotetramers to facilitate HPV16 infection [31]. Interestingly, malignant tissue 150 
from patients with HPV-associated cancers, often poorly express EGFR [63,64]. Further 151 
understanding of the connection between HPV and EGFR is required to fully appreciate this 152 
relationship. 153 
 154 
ErbB-dependent host-directed internalisation and targeting of barrier integrity as well as 155 
ErbB trafficking, appear to be commonly used mechanisms of cellular entry by a diverse 156 
range of pathogens. The development of such distinct pathogen-specific mechanisms to 157 
achieve varied methods of internalisation, all of which utilise EGFR, clearly highlights the 158 
importance of these receptors as significant points of entry into host cells.  159 
 160 
Prolonged host-cell survival through pathogen-mediated EGFR activation 161 
ErbB-mediated host cellular entry is not the only function of this receptor family that is of 162 
potential benefit to invading organisms. ErbB receptors are potent mediators of cellular 163 
growth and survival, and unsurprisingly they have become a commonly exploited target for 164 
this purpose also. The association between Human cytomegalovirus (HCMV) and EGFR has 165 
been well studied. HCMV employs multiple mechanisms of modulating EGFR signalling for 166 
its own propagative benefit, including rapid induction of protein kinase B (PKB, alias Akt) 167 
activation, a protein kinase downstream of Pi3K with important roles in cell cycle regulation. 168 
Cojohari et al. showed that use of MK-2206, a highly selective Akt inhibitor during HCMV 169 
infection, results in decreased viability of infected monocytes [11]. While uninfected cells 170 
utilise the primary isoform of Pi3K (P110δ) for Akt signalling, a switch occurs in HCMV-171 
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infected cells to allow use of the less dominant P110β isoform, resulting in prolonged cell 172 
survival past the 48 h cell-fate check point. While cell viability was dependent on P110δ 173 
activity in uninfected cells, inhibition of this predominant isoform did not cause apoptosis in 174 
HCMV-infected cells, which instead succumbed to cell death following P110β inhibition [11]. 175 
Furthermore, evidence of EGFR-associated promotion of anti-apoptotic proteins, myeloid 176 
leukemia sequence (Mcl-1) and heat shock protein 27 (HSP27) [12], as well as modulation of 177 
negative regulators of cell survival, such as phosphatase and tensin homolong (PTEN) and 178 
SH2 domain-containing inositol 5-phosphatase 1 (SHIP1) [11] has also been shown. In 179 
summary, HCMV appears able to activate EGFR signalling, utilise alternative signalling 180 
molecules in this pathway, and manipulate EGFR to selectively prevent cell apoptosis for its 181 
own propagative benefit. 182 
 183 
Additional mechanisms to modulate the cell cycle via ErbB receptors include HCV-induced 184 
cell survival through amphiregulin release (AREG, an EGFR ligand) [15], Helicobacter pylori 185 
induced cell survival and hyperproliferation via EGFR activation [16] and also Shigella 186 
flexineri promotion of host cell survival through use of phosphatidylinositol 5-phosphate 187 
(PI5P), to impair lysosomal degradation and regulation of EGFR trafficking, as well as 188 
downstream signalling [17]. 189 
 190 
Mechanisms of increasing host infected cell survival appear to involve enhanced ‘growth’ 191 
stimulants while suppressing cell death mechanisms. The observation that HCMV, HCV, H. 192 
pylori and S. flexineri are all capable of invading and surviving within host cells suggests that 193 
their ability to prolong host cell survival is a specific and evolutionary targeted effect, 194 
induced for pathogen benefit. 195 
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 196 
Pathogen induced modulation of immune responses via EGFR: 197 
The ability of pathogens to modulate host immune responses has been long established. 198 
However, the importance of ErbB receptors in this context is less known. A number of 199 
pathogens have been found to manipulate EGFR to promote immune evasion. IAV and 200 
Rhinovirus (RV)-16 are both capable of inhibiting interferon (IFN)-λ production, a critical 201 
antiviral cytokine of the airways, through an EGFR-dependent mechanism that results in 202 
enhanced viral titres [18]. Suppression of CXCL10 (IFN-γ induced protein 10 (IP-10)), a 203 
monocyte and T cell chemokine, has also been shown following IAV, RV or RSV infection, 204 
through virus-induced EGFR signalling [19]. Additionally, NF-kB, a primary transcription 205 
factor governing immune responses, is targeted during Klebsiella pneumoniae infection of 206 
bronchial epithelial cells [65]. Here, the EGFR/Pi3K/Erk signalling pathway is activated to 207 
result in diminished nuclear translocation of NF-kB [66], likely resulting in the suppressed 208 
activation of NF-kB and inflammatory responses observed during K. pneumoniae infection 209 
[65]. 210 
 211 
EGFR activation may also be involved in airway remodelling, which is a hallmark feature of 212 
chronic obstructive pulmonary disease (COPD) and asthma. Airway remodelling refers to the 213 
structural modifications of the airway tissue and can involve increased smooth muscle mass, 214 
sub-epithelial fibrosis and mucous gland hyperplasia which contribute to airflow obstruction 215 
and impairment of lung function. In a model of epithelial cell infection, stimulation with 216 
synthetic double stranded RNA (poly : IC) led to induction of EGFR- and downstream 217 
ERK/p38 MAPK- dependent mucin (MUC)-5AC, transforming growth factor (TGF)-β1, matrix 218 
metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) cytokine 219 
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expression, all of which contribute to airway remodelling [21]. Pseudomonas aeruginosa 220 
[25] and poly(I:C)-mediated [26] activation of EGFR, also enhanced MUC5AC and 221 
subsequent mucus hypersecretion, which contributed to airway mucus obstruction during 222 
respiratory disease [25,26]. 223 
 224 
Retention of MHC-I molecules at the Golgi, by the bacterium Brucella abortus is another 225 
example of immune evasion via ErbB receptors and results in inhibited MHC-I surface 226 
expression [22,67]. Inhibition of EGFR, ErbB2 or the ErbB ligand sheddase protein, tumour 227 
necrosis factor-α-converting enzyme (TACE/ADAM17), was each able to modestly recover 228 
MHC-I surface expression, whilst Erk1/2 inhibition led to significant restoration of MHC-I 229 
surface expression [22]. Furthermore, exposure of the monocyte/macrophage cell-line THP-230 
1, to exogenous EGF, TGF-α or a combination of the two EGFR ligands, was able to mimic B. 231 
abortus-induced retention of MHC-I at the Golgi and reduced surface MHC-I expression. 232 
 233 
Interestingly, Hepatitis B virus (HBV) can promote immune evasion by inducing tolerance. 234 
Surface EGFR is upregulated on HBV infected intrahepatic regulatory T cells (Treg), which 235 
enhances their immunosuppressive capacity [68]. HBV-infected mice exhibited increased 236 
numbers of Treg cells that expressed immunosuppressive cytokines such as interleukin (IL)-237 
10 and TGF-β, in addition to an enhanced ability to prevent CD8+ T cell proliferation, a 238 
requirement for HBV clearance [68]. HCMV induced latency is another interesting tactic 239 
providing immune evasion and also governed by EGFR activity. During infection, ability to 240 
induce latency-associated UL138, while suppressing IE1/IE2 lytic genes, was shown to be 241 
EGFR dependent, by use of EGFR specific inhibitors [69]. Additionally, Mycobacterium 242 
tuberculosis can utilise EGFR-induced p38/MAPK signalling pathways within macrophages, 243 
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to prevent proper anti-microbial macrophage responses, resulting in enhanced murine 244 
infection [70]. However, in contrast to these pathogen-driven functions of EGFR that 245 
contribute to infection, some EGFR-induced host protective functions have also been 246 
observed. One study highlights the requirement of EGFR in macrophage activation and 247 
function against H. pylori bacteria, where EGFR-deficient macrophages exhibited impaired T 248 
helper (Th)1 and Th17 adaptive responses, resulting in suppressed H. pylori-induced chronic 249 
inflammation and disease progression in mice [71]. Additionally, EGFR-dependent S. aureus-250 
induced IL-1α and IL-1β [23], as well as E. coli- [24] and virus induced [72–74] IL- 8, may be 251 
examples of host-beneficial EGFR-dependent responses induced by pathogens.  252 
 253 
Together, these studies highlight a complexity of EGFR functionality, which has ability to 254 
both contribute to and protect against infections. Mechanisms for immune modulation are 255 
highly diverse and pathogen-specific, perhaps emphasising the strength of our intricate 256 
immune system and the specialisms of each microbial species. The observation that 257 
pathogens are able to augment cellular immune responses through EGFR signalling, again 258 
highlights the importance of this class of receptors during infection. 259 
 260 
ErbB associated cancers 261 
ErbB receptor activity is highly associated with oncogenic transformation. Several cancers, 262 
including head and neck squamous cell carcinoma (HNSCC), lung and colon cancers, are 263 
known to result from aberrant ErbB expression or signalling. Aberrations leading to 264 
overexpressed or constitutively active ErbB receptors [75–77], overproduced ErbB receptor 265 
ligands [15,78–83] and sheddases that cleave ErbB precursor ligands into their mature forms 266 
[84–87], have all been shown to cause cellular transformation. Thus, it is perhaps 267 
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unsurprising that several cancer-inducing pathogens have been found to promote ErbB 268 
activation, with evidence of cellular transformation being directly caused by pathogen 269 
induced ErbB signalling. In fact, the ErbB signalling pathway has been implicated in a 270 
number of major oncogenic virus infections.  271 
 272 
For example, HBV has been shown to induce upregulated expression of EGFR gene and 273 
protein, both of which are strongly associated with hepatocellular transformation [88,89]. 274 
This virus is also thought to enhance ErbB2 mRNA stability through the HBV-encoded X-275 
protein (HBx), which is itself strongly associated with hepatocellular carcinoma (HCC), 276 
resulting in enhanced HCC cell migration [90]. Likewise, HCV infection results in enhanced 277 
surface EGFR expression [29,61], EGFR activation and consequent viral entry [28], whilst 278 
patients exhibiting certain EGFR polymorphisms spontaneously clear HCV infection [91]. 279 
HCV induced AREG overexpression in human hepatoma cells, contributes to prolonged 280 
infected-cell survival, cirrhosis and HCC progression [15]. Furthermore, EGFR, which can also 281 
be cleaved from apoptotic cells to shut down signalling [92], is found in significantly higher 282 
concentrations in HCC patient plasma, in the presence of HCV and HBV infection [93]. 283 
Whether this reflects host attempts to curtail aberrant cell proliferation, or is merely a by-284 
product of virus induced apoptosis, remains unclear. So consistent is the increase in soluble 285 
EGFR during virus-induced HCC, that it may serve as a marker for such disease [93].  286 
 287 
HPV is another virus which has been associated with both EGFR and oncogenesis. 288 
Interestingly, in this case, EGFR expression is commonly low [63,64] and has been an area of 289 
detailed investigation. One explanation for the existence of ‘HPV-positive EGFR-negative’ 290 
malignancies could lie in the functional redundancy between ErbB receptors as well as an 291 
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ability of family members to regulate expression of each other. Indeed, several studies have 292 
highlighted an over-expression of ErbB2 and ErbB3 receptors, or even ErbB3 dependency 293 
[94], in HPV-positive cancers [95–97], whilst Stindt et al. showed that HCV induced 294 
downregulation of ErbB3, upregulates EGFR and ErbB2 expression on hepatocytes [29]. 295 
These results were reproducible following suppression of ErbB3 with siRNAs and suggests 296 
that ErbB3 can function to impact on the expression of EGFR and ErbB2 [29]. However, the 297 
presence of ‘HPV-positive EGFR-positive’ malignancies has also been observed [98,99]. 298 
Together, these examples highlight an association between HPV-induced cancer and ErbB 299 
receptors, though the full extent of receptor contribution to such disease remains 300 
incompletely understood. 301 
 302 
Other oncogenic viruses found to have association with EGFR include Epstein Barr Virus 303 
(EBV), whose virus-encoded LMP1 protein induces EGFR expression [30], Kaposi’s Sarcoma-304 
associated Herpesvirus (KSHV), which promotes EGFR activation [100] and human T cell 305 
leukaemia virus (HTLV), shown to directly induce EGFR-dependent cellular transformation 306 
[101]. 307 
 308 
Additionally, bacteria-induced EGFR-dependent oncogenesis has been documented. The 309 
association between H. pylori and gastric cancer is highly acknowledged, with studies 310 
suggesting that this pathogen remains the strongest known risk factor for stomach 311 
tumorigenesis. Early clearance of infection significantly lowers the risk of malignancies 312 
[102], which supports its role as a carcinogen and crucially, H. pylori infections are strongly 313 
linked to the dysregulation of EGFR ligands and/or transactivation of EGFR (reviewed in 314 
[103]). The ability of H. pylori to dephosphorylate EGFR, is particularly interesting. Pathogen 315 
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induced inactivation of EGFR involves activation of host SHP2 tyrosine phosphatase, to 316 
result in suppression of the antimicrobial peptide, human beta-defensin 3 (hBD3) 317 
expression, to which H. pylori is highly susceptible, and sustained bacterial infection [104]. 318 
 319 
It is curious to note that the ErbB-dependent oncogenic pathogens mentioned herein are 320 
capable of replicating intracellularly. Coupled with their ability to induce hyperproliferation, 321 
it would be interesting to investigate the role of host cell turnover in ErbB-dependent 322 
pathogen survival. Several viruses (HBV, HCV, EBV and HPV among others) are known to 323 
require host machinery for protein synthesis and subsequent viral replication; these host 324 
translational apparatus can be found in greater abundance at specific points during host cell 325 
cycle [105]. As such, subversion of the cell cycle is a common theme where both cycle arrest 326 
and induction may occur [106], however the effect of either on associated disease remains 327 
unclear. Indeed, not all viruses possessing the ability to regulate the cell cycle, such as IAV 328 
and SARS viruses, are particularly associated with oncogenesis. Further investigation into 329 
the precise requirements of oncogenic pathogens, leading to host cell survival and 330 
replication, and the role of ErbB receptors in this context, may provide valuable insights to 331 
developing more effective cancer therapies. 332 
 333 
Concluding remarks and future perspectives 334 
There exists a growing body of evidence to support the role of the ErbB receptor family as a 335 
critical regulator of pathogen invasion and propagation within the human host. Numerous 336 
studies have highlighted pathogen-selective exploitation of ErbB receptors as a mechanism 337 
that contributes to host cell entry, cell survival, augmentation of host immunity and cancer 338 
(Fig 1, Key Figure). Their cellular localisation, regulated mode of internalised recycling and 339 
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functional capacity, make the ErbB family an excellent target for pathogens that require 340 
access into host cells in order to self-replicate. Several ErbB-dependent pathogens show 341 
capacity to regulate the cell cycle to access host machinery, however the direct effects of 342 
this on prolonging host cell survival or enhancing proliferation remain undefined. 343 
Malignancies do not occur as a result of all infections and suggests there are likely other 344 
factors involved in driving cellular transformation during infection.  345 
 346 
On a grander scale, the role of host ErbB receptors during infection is an overlooked aspect 347 
of disease which warrants deeper consideration. To date, research in this context has 348 
focused predominantly on viral pathogens, with much less detail known regarding bacterial 349 
and fungal infections.  Investigations are also skewed toward the more prominent EGFR and 350 
interest in this host receptor may be warranted as it is the only ErbB member to undergo 351 
ligand-induced internalisation, greatly enhancing its appeal for pathogen exploitation. 352 
However, given the functional redundancy of ErbB receptors and their potential to regulate 353 
expression of each other [29], it would be remiss not to fully investigate the role of all family 354 
members.  With drug resistance increasing in a plethora of pathogens, there is an 355 
immediate and critical need for the development of innovative therapies that target novel 356 
factors. As such, ErbB receptors and associated signalling pathways may possess potential 357 
value as novel therapeutic targets during pathogenic infection. This notion is supported by a 358 
recent study which validates the efficacy of the specific EGFR inhibitor Erlotinib, in 359 
conjunction with a broad spectrum tyrosine kinase inhibitor Sunitinib, against a range of 360 
evolutionary distinct viral pathogens [107]. Both drugs have FDA approval as 361 
immunomodulatory cancer therapies and would also be exciting prospects as novel anti-362 
microbial drugs. However, toxicity concerns that include adverse skin conditions, diarrhoea 363 
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and heart failure may warrant limitation of their use to treatment of more serious 364 
infections.  365 
 366 
The future of both research and therapies surrounding ErbB receptors is continually 367 
expanding and the next decade should reveal some intriguing and critical information 368 
regarding the interaction between microbes and these receptors. 369 
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Key Fig: Primary mechanisms and targets modulated or induced by microbes, involving 
ErbB receptors. 
Pathogen induced mechanisms of host cell entry can involve (A): ErbB-mediated lipid raft 
clustering, (B): inhibition of ErbB endocytosis resulting in elevated surface receptor 
expression, (C): ErbB-mediated macropinocytosis and (D): modulation of junction proteins. 
Pathogens can also manipulate factors that govern immune responses through ErbB 
receptor exploitation. Mechanisms here include (E): altering cytokine expression in infected 
cells and (F): inhibition of NF-ĸB nuclear-translocation. Additionally some pathogens that are 
able to regulate the cell cycle also appear able to induce host cell survival, proliferation or 
oncogenesis (G). 
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Outstanding questions box: 
 The EGFR has been associated with lipid raft clustering and viral entry mechanisms, 
but lipid raft aggregation is also involved in viral egress. Does EGFR, therefore, play a 
role during budding of nascent viral progeny? 
 
 Both enhanced cell turnover and barrier integrity have been shown to be protective 
against pathogen invasion, factors that ErbB receptors are directly capable of 
inducing. Is there potential to enhance this protective role of ErbB receptors as a 
preventative measure against infection? 
 
 How efficacious would current ErbB targeted therapies be against pathogen 
infection in humans? Toxicity and resistance against such drugs has been observed in 
cancer patients. Are the mechanisms behind such events relevant in the setting of 
pathogenic infection?  
 
 Is ErbB receptor function capable of directly driving pathogen-induced cellular 
transformation? If so, at which stage(s) of cancer does this contribute? During initial 
oncogenesis or maintenance and progression of cancer? 
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Table 1: ErbB-dependent microbes and their mechanisms of receptor exploitation 
Virus Mechanism of ErbB exploitation Outcomes Ref. 
EBV Induces of EGFR expression Host cell 
proliferation  
[30] 
HBV Induces of surface EGFR expression Host cell 
proliferation 
[88,89] 
HCV Disrupts EGFR recycling to enhance surface 
expression through host protein Netrin-1 
Host cell entry [27] 
Enhances EGFR and ErbB2 surface 
expression through NRG-1 dependant 
mechanism 
[29] 
Induces AREG-dependant circumvention of 
apoptosis; induces proliferation and 
transformation 
Host cell survival 
and proliferation 
[15] 
HCMV Alters EGFR signalling molecules to bypass 
cell-fate check points and enhance 
production of cell cycle proteins 
Host cell survival  [11,12] 
 EGFR activation promotes latency by 
inducing latent, but suppressing of lytic 
gene expression 
Immune evasion [69] 
HPV Induces EGFR-dependent translocation of 
AnxA2 results in formation of the HPV-
AnxA2-S100A10 binding complex required 
for viral entry  
Host cell entry [31] 
HTLV Induces EGFR activation resulting in cellular 
transformation in CD4+ Tcells 
Host cell 
proliferation 
[101] 
IAV 
 
 
Induces of lipid raft clustering. Activates 
EGFR and other RTKs leading to cellular 
internalisation 
Host cell entry [35] 
Suppresses IFN-λ and CXCL10 through EGFR 
activation 
Immune 
modulation 
 
[18,19] 
KSHV Oncogenic pathogen induces activation of 
EGFR signalling  
Unconfirmed [100] 
RV 
 
Suppresses RV-induced IFN-λ and CXCL10 
expression via EGFR activation 
Immune 
modulation 
 
[18,19] 
RSV 
 
 
Induces EGFR dependent macropinocytosis Host cell entry [32,33] 
Suppresses RSV-induced CXCL10 expression 
via EGFR activation 
Immune 
modulation 
[19] 
SARS Induces EGFR dependent macropinocytosis Host cell entry [34] 
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Table 1 continued:  
Bacteria Mechanism Outcomes Ref. 
Brucella abortus Inhibits MHC-I expression 
potentially involving EGFR, ErbB2 
and/or TACE sheddase. 
Immune 
modulation 
[22,67] 
Campylobacter 
jejuni 
Induces lipid raft clustering and 
EGFR activation 
Host cell entry [44] 
Chlamydia 
pneumoniae 
Bacterial Pmp21 adhesin directly 
binds EGFR 
Host cell entry [10] 
Escherichia coli Disrupts endosome trafficking 
resulting in diminished surface EGFR  
Unconfirmed [62] 
Helicobacter 
pylori 
Induces EGFR dependent β-catenin 
nuclear translocation and PI3K/Akt 
signalling 
Host cell 
survival 
[16] 
Dephosphorylates EGFR to inhibit 
hBD3 expression and promote 
infection 
Immune 
modulation 
[104] 
Klebseilla 
pneumoniae 
Induces EGFR dependent inhibition 
of NF-kB translocation 
Immune 
modulation 
[65,66] 
Neisseria 
gonorrhoeae 
Induces redistribution of β-catenin 
from apical junction to cytoplasm 
through EGFR activation.  
Host cell entry [51] 
Induces translocation of ErbB2 and 
ErbB3 to apical surfaces 
[61] 
Neisseria 
meningitidis 
Recruits and activates ErbB2 
receptors 
Host cell entry [2] 
Mycobacterium 
leprae 
Directly binds ErbB2 receptors Host cell entry [14] 
Mycobacterium 
tuberculosis 
Prevent proper macrophage 
function resulting in enhanced 
infection 
Immune 
modulation  
[70] 
Salmonella 
Typhimurium 
Induces Claudin 2 expression 
through EGFR and downstream JNK 
activation 
Host cell entry [50] 
Shigella flexineri Induces PI5P production to regulate 
EGFR trafficking  
Host cell 
survival 
[17] 
Staphylococcus 
aureus 
Cleaves junction proteins occludin 
and E-cadherin to facilitate 
transmigration. EGFR activation is 
required 
Host cell entry [13] 
Fungi Mechanism Outcomes  Ref. 
Candida 
albicans 
EGFR and ErbB2 dependent 
endocytosis 
Host cell entry [55,56] 
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Trends box: 
 A wide and diverse variety of microbes have each evolved distinct mechanisms to 
exploit ErbB receptors, highlighting this receptor kinase family as a critical factor in 
initiation and maintenance of pathogen infections. 
 ErbB family members are utilised by pathogens attempting to gain cellular entry, 
subvert immune responses, and manipulate the cell cycle of infected host cells. 
These events support and are necessary for pathogen persistence. 
 Pathogen-mediated ErbB-exploitation may contribute to cellular transformation and 
oncogenesis in a variety of cancers.  
 The use of existing FDA approved drugs that target ErbB receptors and associated 
signalling components may offer potential future therapies against infection. 
 
 
